Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96RE7
UPID:
NACC1_HUMAN
Alternative names:
BTB/POZ domain-containing protein 14B
Alternative UPACC:
Q96RE7
Background:
Nucleus accumbens-associated protein 1, also known as BTB/POZ domain-containing protein 14B, plays a crucial role in the cellular mechanisms underlying neurodevelopment and tumor progression. It functions as a transcriptional repressor, influencing neuronal cell activity and tumor cell proliferation by recruiting HDAC3 and HDAC4, and modulating proteasome localization.
Therapeutic significance:
Linked to a neurodevelopmental disorder with epilepsy, cataracts, and delayed brain myelination, understanding the role of Nucleus accumbens-associated protein 1 could open doors to potential therapeutic strategies for these severe conditions.